《低葡萄糖降解产物腹膜透析液》ppt课件.pptVIP

低葡萄糖降解产物腹膜透析液; 腹膜透析;Worldwide prevalence of peritoneal dialysis in 2006 expressed as a percentage of the total dialysis population;Other countries 17 万;与普通HD比较CAPD的优势;腹膜透析的主要问题;低葡萄糖降解产物腹膜透析液; 葡萄糖;二、低葡萄糖降解产物腹透液的研究进展; 1、渗透剂的研究; 氨基酸腹透液; 氨基酸腹透液（国外研究）;1.1%氨基酸腹膜透析液减少患者氨基酸和蛋白质的丢失; ; Nephrol Dial Transplant (2003) 18: 1086–1094; Control: A: 5 mM D-glucose Experimental conditions: B: 30 mM D-glucose C、E: spent Dianeal D、F: Nutrineal; 氨基酸腹透液（国内研究-1）; 氨基酸腹透液（国内研究-2）; 多肽腹透液;An integrin-activating peptide, PHSRN, ameliorates inhibitory effects of conventional peritoneal dialysis fluids on peritoneal wound healing; Wound-healing process after peritoneal injury induced by stripping of the mesothelial cell monolayer.; Effects of PHSRN on pathological changes; 多聚糖(Icodextrin)腹透液; 多聚糖腹膜透析液研究进展;对腹膜间皮细胞活性的影响 ;Smaller increase in TGF-?1 in vitro;多聚糖腹膜透析液延缓腹膜透析液引起的腹膜功能的恶化，延长腹膜透析使用的时间;Histological appearance of peritoneum;Vascular endothelial growth factor (VEGF) expression was evaluated by a VEGF immunostaining of the peritoneum;Fibrosis was evaluated with fibronectin immunostaining of the peritoneum;Basic fibroblast growth factor (bFGF) expression was evaluated by a bFGF immunostaining of the peritoneum;Advanced glycation end-product (AGE) accumulation was evaluated by an AGE immunostaining of the peritoneum;(19)Schalkwijk et al.,?Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis fluids based on glucose polymers or amino acids. Perit Dial Int 2000;20:796-798.;Reduced AGE FormationCML* Generation–Icodextrin vs Dextrose;With the same risk factors, patients using Extraneal (usually older), have a 32% reduced risk of transfer to HD. ;Patients Reporting Better Health (%);Icodextrin 优缺点总结 ; 其他成分腹膜透析液;2、包装方式改良的双室双袋腹膜透析液的研究; 双室双袋腹膜透析液优势;三、低葡萄糖降解产物腹透液的主要优势; 1、改善生物相容性;低GDPs腹??透析液-腹膜间皮细胞完整性指标CA125水平较高;低GDPs腹膜透析液较传统腹膜透析液明显降低患者血AGE水平; 2、减少腹膜炎; 3、